Clinical Trial Update: Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A status update on a phase 1/2 trial evaluating the combination of ibrutinib and trastuzumab for HER2-amplified metastatic breast cancer, which is currently not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: US Oncology Research | Conditions: Breast Neoplasms, Malignant Neoplasm of Breast | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING